More than 50 years of landmark results
Since 1967, Lowey Dannenberg has represented investors and major corporations in complex litigation, recovering billions of dollars on their behalf.Solutions for Complex Cases
Professional Recommendations
Recent Cases

Roche v. Aetna, Inc.
Healthcare, Notable
Lowey Dannenberg is defending Aetna in a class action related to state anti-subrogation laws. Minerley v. Aetna Inc., et al., 13-cv-1337 (D.N.J.). Lowey Dannenberg has defended and won dismissal of several similar class action lawsuits against health insurance clients: Wurtz v. Rawlings Co., LLC, 2016 WL 7174674 (E.D.N.Y. Nov. 17, 2016); Meek-Horton v. Trover, et al., 910 F.Supp. 2d 690 (S.D.N.Y. 2013); Potts v. Rawlings Co. LLC, 897 F.Supp. 2d 185 (S.D.N.Y. 2012).

Federated Investment Management Company, et al., v. Republic of Argentina
Antitrust
Lowey obtained emergency injunctive relief on behalf of Federated Investors, one of the largest investment firms in the country with over $363 billion in assets under management, preventing the Government of Argentina from canceling outstanding bonds with a face value of more than $500 million, which had been erroneously tendered by those bondholders. Federated Investment Management Company, et al., v. Republic of Argentina, et al., 10 Civ. 4324 (S.D.N.Y. 2010) (Griesa, J.).

Juniper Networks
Notable
Lowey Dannenberg served as lead counsel, representing the New York City Pension Funds and related class members, alleging that Juniper Networks, Inc. fraudulently concealed the backdating of millions of stock options, resulting in a $900 million financial restatement.
News
Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating claims of violations of federal securities laws on behalf of investors of Penumbra Inc. (“Penumbra” or the “Company”) (NYSE: PEN).
Penumbra, Inc. designs, develops, manufactures, and markets medical devices. The Company offers peripheral vascular and neurovascular devices that help patients suffering from stroke and other neurovascular diseases.
Blog
AECPA’s Failure to Address Monopolists’ Abuse of Arbitration Is Bad For Everyone
Last month I had the opportunity to help organize a CLE webinar with the New York State Bar Association on the topic of a new Senate legislation, the Anticompetitive Exclusionary Conduct Prevention Act (AECPA). The discussion was led by leading antitrust academics and practitioners: Seton Hall…





